Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management

被引:42
|
作者
Mustafa, S. Shahzad [1 ,2 ]
Ostrov, David [3 ]
Yerly, Daniel [4 ,5 ]
机构
[1] Rochester Reg Hlth Syst, Allergy & Clin Immunol, Rochester, NY 14611 USA
[2] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA
[3] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA
[4] Univ Hosp, Dept Rheumatol Immunol & Allergol, Bern, Switzerland
[5] Univ Bern, Bern, Switzerland
关键词
Severe cutaneous adverse drug reaction(SCAR); Acute generalized exanthematous pustulosis(AGEP); Drug reaction with eosinophilia and systemic symptoms (DRESS); Stevens-Johnson syndrome (S[!text type='JS']JS[!/text]); Toxic epidermal necrolysis (TEN); HLA-associated drug hypersensitivity; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; GENERALIZED EXANTHEMATOUS PUSTULOSIS; COLONY-STIMULATING FACTOR; AMNIOTIC MEMBRANE TRANSPLANTATION; INTRAVENOUS IMMUNOGLOBULIN; DRESS SYNDROME; HYPERSENSITIVITY SYNDROME; RETROSPECTIVE ANALYSIS; SYSTEMIC SYMPTOMS;
D O I
10.1007/s11882-018-0778-6
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Purpose of Study Immune-mediated adverse drug reactions occur commonly in clinical practice and include mild, self-limited cutaneous eruptions, IgE-mediated hypersensitivity, and severe cutaneous adverse drug reactions (SCAR). SCARs represent an uncommon but potentially life-threatening form of delayed T cell-mediated reaction. The spectrum of illness ranges from acute generalized exanthematous pustulosis (AGEP) to drug reaction with eosinophilia with systemic symptoms (DRESS), to the most severe form of illness, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Recent Findings There is emerging literature on the efficacy of cyclosporine in decreasing mortality in SJS/TEN. Summary The purpose of our review is to discuss the typical presentations of these conditions, with a special focus on identifying the culprit medication. We review risk factors for developing SCAR, including HLA alleles strongly associated with drug hypersensitivity. We conclude by discussing current strategies for the management of these conditions.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management
    S. Shahzad Mustafa
    David Ostrov
    Daniel Yerly
    Current Allergy and Asthma Reports, 2018, 18
  • [2] Management of severe cutaneous adverse drug reactions to corticosteroids
    Waton, J.
    Baeck, M.
    Torres, M.
    Barbaud, A.
    REVUE FRANCAISE D ALLERGOLOGIE, 2013, 53 (03): : 298 - 303
  • [3] Ethical considerations in the management of drug severe cutaneous adverse reactions
    Buckey, Timothy M.
    Ferreira, Alana L.
    Grant-Kels, Jane M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (04) : 964 - 965
  • [4] Severe cutaneous adverse drug reactions
    Chung, Wen-Hung
    Wang, Chuang-Wei
    Dao, Ro-Lan
    JOURNAL OF DERMATOLOGY, 2016, 43 (07): : 758 - 766
  • [5] Severe Cutaneous Adverse Drug Reactions
    Schroeder, J.
    DRUG SAFETY, 2013, 36 (09) : 942 - 942
  • [6] Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions
    Wang, Chuang-Wei
    Dao, Ro-Lan
    Chung, Wen-Hung
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 16 (04) : 339 - 345
  • [7] Treatment of severe cutaneous adverse drug reactions
    Ingen-Housz-Oro, S.
    Duong, T-A
    de Prost, N.
    Colin, A.
    Fardet, L.
    Lebrun-Vignes, B.
    Barbaud, A.
    Chosidow, O.
    Wolkenstein, P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (6-7): : 454 - 464
  • [8] Recognising severe cutaneous adverse drug reactions
    Chee, Paul
    MEDICAL JOURNAL OF AUSTRALIA, 2017, 207 (08) : 325 - +
  • [9] The assessment of severe cutaneous adverse drug reactions
    Copaescu, Ana M.
    Trubiano, Jason A.
    AUSTRALIAN PRESCRIBER, 2022, 45 (02) : 43 - 48
  • [10] Approach to Severe Cutaneous Adverse Drug Reactions
    Bellón T.
    Cabañas R.
    González-Herrada C.
    Ramírez E.
    González-Ramos J.
    López San Martín M.
    González-Valle O.
    Fiandor A.M.
    Lerma V.
    Roustan G.
    de Abajo F.
    Current Treatment Options in Allergy, 2017, 4 (2) : 201 - 221